NCT06011772 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT06011772
Title	EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
Recruitment	Active, not recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Roswell Park Cancer Institute
Indications	colon adenocarcinoma rectum adenocarcinoma
Therapies	CIMAvax-EGF Bevacizumab + Cetuximab + CIMAvax-EGF + Leucovorin Bevacizumab + CIMAvax-EGF + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + CIMAvax-EGF + Fluorouracil + Oxaliplatin Cetuximab + CIMAvax-EGF + Fluorouracil + Irinotecan + Leucovorin
Age Groups:	senior \| adult
Covered Countries	USA

Additional content available in CKB BOOST